Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002140 · ClinicalTrials.gov registry record · Phase 3
A Randomized, Double-Blind, Comparative Study of Azithromycin Versus Clarithromycin in Combination With Ethambutol for the Treatment of Disseminated Mycobacterium Avium Complex (MAC) Infection in AIDs Patients
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
NCT00002140: Completed Phase 3 study, sponsored by Pfizer.
NCT00002140 is a Phase 3 study that has completed, run by Pfizer. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002140, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
To evaluate the efficacy and safety of two different doses of azithromycin in combination with ethambutol for the treatment of patients with Mycobacterium avium complex (MAC) infection, and to determine whether an azithromycin-containing regimen is at least as safe and effective as the same regimen containing clarithromycin..
Interventions
- DRUG Azithromycin
- DRUG Clarithromycin
- DRUG Ethambutol hydrochloride
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 3 |
What the finished NCT00002140 record still lists
NCT00002140 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 3 interventions - of which Azithromycin is the first listed.
NCT00002140 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002140 about?
NCT00002140 is a clinical study titled "A Randomized, Double-Blind, Comparative Study of Azithromycin Versus Clarithromycin in Combination With Ethambutol for the Treatment of Disseminated Mycobacterium Avium Complex (MAC) Infection in AIDs Patients". To evaluate the efficacy and safety of two different doses of azithromycin in combination with ethambutol for the treatment of patients with Mycobacterium avium complex (MAC) infection, and to determine whether an azithromycin-containing regimen is at least as safe and effective as the same regimen ...
What is the current status of trial NCT00002140?
This trial is currently completed. It is a Phase 3 study.
What interventions are being tested in trial NCT00002140?
The interventions under investigation include: Azithromycin (DRUG), Clarithromycin (DRUG), Ethambutol hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00002140?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.